ATXS
Price
$5.22
Change
-$0.06 (-1.14%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
294.59M
67 days until earnings call
LRMR
Price
$2.46
Change
+$0.01 (+0.41%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
157.51M
63 days until earnings call
Interact to see
Advertisement

ATXS vs LRMR

Header iconATXS vs LRMR Comparison
Open Charts ATXS vs LRMRBanner chart's image
Astria Therapeutics
Price$5.22
Change-$0.06 (-1.14%)
Volume$3.98K
Capitalization294.59M
Larimar Therapeutics
Price$2.46
Change+$0.01 (+0.41%)
Volume$1.8K
Capitalization157.51M
ATXS vs LRMR Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. LRMR commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and LRMR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ATXS: $5.22 vs. LRMR: $2.46)
Brand notoriety: ATXS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 54% vs. LRMR: 64%
Market capitalization -- ATXS: $294.59M vs. LRMR: $157.51M
ATXS [@Biotechnology] is valued at $294.59M. LRMR’s [@Biotechnology] market capitalization is $157.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while LRMR’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 4 bearish.
  • LRMR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than LRMR.

Price Growth

ATXS (@Biotechnology) experienced а +5.45% price change this week, while LRMR (@Biotechnology) price change was +6.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

LRMR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($295M) has a higher market cap than LRMR($158M). LRMR YTD gains are higher at: -36.693 vs. ATXS (-40.940). LRMR has higher annual earnings (EBITDA): -105.02M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. LRMR (158M). LRMR has less debt than ATXS: LRMR (4.87M) vs ATXS (5.35M). ATXS (0) and LRMR (0) have equivalent revenues.
ATXSLRMRATXS / LRMR
Capitalization295M158M187%
EBITDA-111.56M-105.02M106%
Gain YTD-40.940-36.693112%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M158M208%
Total Debt5.35M4.87M110%
FUNDAMENTALS RATINGS
ATXS vs LRMR: Fundamental Ratings
ATXS
LRMR
OUTLOOK RATING
1..100
1965
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
8893
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (20) in the null industry is somewhat better than the same rating for ATXS (58) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than ATXS’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (94) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ATXS’s stock grew similarly to LRMR’s over the last 12 months.

ATXS's Price Growth Rating (88) in the Biotechnology industry is in the same range as LRMR (93) in the null industry. This means that ATXS’s stock grew similarly to LRMR’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ATXS’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSLRMR
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 28 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAZBX36.370.05
+0.14%
Oakmark Equity and Income R6
SBICX9.57N/A
N/A
ClearBridge International Value C
PPYAX8.34N/A
N/A
PIMCO RAE International A
CSCZX48.84N/A
N/A
Columbia Small Cap Value I Inst
HLPPX9.87N/A
N/A
LDR Real Estate Value Opportunity P

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+6.45%
TRDA - ATXS
53%
Loosely correlated
-3.76%
KYMR - ATXS
53%
Loosely correlated
+1.56%
CRNX - ATXS
53%
Loosely correlated
+0.78%
XENE - ATXS
51%
Loosely correlated
-0.85%
DNLI - ATXS
51%
Loosely correlated
+3.52%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+1.66%
ERAS - LRMR
53%
Loosely correlated
+5.88%
IMNM - LRMR
50%
Loosely correlated
-2.59%
ACLX - LRMR
50%
Loosely correlated
+0.52%
ATXS - LRMR
49%
Loosely correlated
+6.45%
COGT - LRMR
47%
Loosely correlated
-2.59%
More